+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting a Phase 3, multicenter, open-label study to evaluate the pharmacokinetics and safety of dupilumab in children and adolescents aged 6 months to under 18 years who have prurigo nodularis. This condition requires participants to have a clinical diagnosis with specific lesion and itch severity criteria to be included. The study aims to better understand how dupilumab behaves in the body and its safety profile in this population. Participants will receive dupilumab administered subcutaneously, with dosing based on their weight and age. The study includes three distinct periods a screening period lasting 2 to 4 weeks, a treatment period of 24 weeks during which dupilumab is given, and a post-intervention follow-up period lasting 16 weeks. The total participation time is approximately 42 to 44 weeks, and there will be six planned study visits for each participant. During the study, participants and caregivers will complete daily symptom e-diaries to track itch severity and other symptoms. Researchers will monitor the concentration of dupilumab in the blood from Day 1 through Week 40, as well as the incidence of any treatment-related adverse events and the development of anti-drug antibodies. Safety and effectiveness will be assessed throughout the treatment and follow-up periods, ensuring thorough observation over the entire study duration.

Age: 6Months - 17YearsAll GendersPhase 3
15 locations
R

Actively Recruiting

This observational study aims to understand the effects of etrasimod as a treatment for adults with moderate to severe ulcerative colitis who have not taken etrasimod before. Patients will receive etrasimod as part of their usual care, with treatment decisions made by their doctors based on what is best for each patient. Participants will be prescribed etrasimod according to standard medical practice. During the 52-week study period, patients will complete health questionnaires about ulcerative colitis symptoms using a mobile phone, tablet, or computer. Usual tests and doctor visits will follow standard care. After the 52 weeks, there will be a 28-day safety follow-up. Researchers will compare each patients disease activity before and after starting etrasimod, focusing on the proportion of patients who achieve symptom remission at 12 weeks as the main outcome. Additional outcomes include symptom responses and remission at later time points, changes in fatigue, bowel urgency, and abdominal pain. Patients will be monitored through regular questionnaires and standard medical visits throughout the study period.

Age: 18Years - 64YearsAll Genders
29 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of fusidic acid 1% eye drops compared to a placebo for treating bacterial conjunctivitis in both adults and children. This Phase 3 clinical trial aims to show that fusidic acid 1% is superior to placebo in curing bacterial conjunctivitis and to further confirm its safety when applied topically to the eyes. Participants will be randomly assigned to one of two groups one group will apply one drop of fusidic acid 1% in each eye twice daily for seven days, and the other group will use a placebo eye drop with the same schedule. The doses are ideally spaced about 12 hours apart, but the twice-daily application schedule is prioritized over exact timing. During the study, participants will be assessed for clinical cure and microbial eradication at Day 4 and Day 8 visits. Researchers will monitor safety and treatment effects through these evaluations and by tracking any adverse events. The total participation duration covers at least the seven days of treatment plus follow-up assessments, helping establish both effectiveness and safety profiles for the treatment.

All AgesAll GendersPhase 3
38 locations
V

Actively Recruiting

Researchers are evaluating the FebriDx test to determine how well it distinguishes between bacterial and non-bacterial causes in children aged 2 to 11 years who have a fever and suspected acute respiratory infection. This observational study involves febrile pediatric patients presenting to emergency departments, urgent care centers, or primary care offices. The goal is to assess the tests ability to detect a bacterial systemic immune response compared to expert clinical adjudication using a clinical reference algorithm including pathogen detection and immune response measures. The study involves using the FebriDx device, a rapid lateral flow immunoassay that detects elevated levels of host response proteins Myxovirus resistance protein A MxA and C-reactive protein CRP from a fingerstick blood sample. Children suspected of acute respiratory infection will undergo the FebriDx test during a single visit. The study is blinded and observational without experimental treatments or placebo groups. Participants will be assessed once at enrollment with the FebriDx test and clinical data collection. Researchers will review clinical signs, symptoms, and results from pathogen detection tests such as bacterial culture or multiplex PCR to adjudicate infection status. Follow-up includes a 7-day period to monitor outcomes. The main outcome measure is the performance of the FebriDx test in identifying bacterial infections on the day of testing.

Age: 2Years - 11YearsAll Genders
10 locations
P

Actively Recruiting

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.

Age: 65Years +All GendersPhase 3
789 locations